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Double inversion of the long arm of chromosome 3 
Note 
Inv(3)(q21q26) is recognized as a distinctive entity of 
acute myeloid leukemia (AML) with recurrent genetic 
abnormalities of prognostic significance. The molecular 
consequence is the juxtaposition of the ribophorin I 
(RPN1) gene (located in band 3q21) with the ecotropic 
viral integration site 1 (EVI1) gene (located in band 
3q26.2), resulting in over-expression of EVI1 (Bitter et 
al., 1985; Suzukawa et al., 1994).  
Inv(3)(q21q26) in two copies is rare and was first 
described by Walter et al. in 1990. 




This is a rare chromosomal rearrangement, described in 
only ten patients with myeloid diseases to date (Walter 
et al., 1990; Levy et al., 1994; Secker-Walker et al., 
1995; Lee, 1999; Lahortiga et al., 2004; Toydemir et 
al., 2010; Lugthart et al., 2010; De Braekeleer et al., 
2013). 
Phenotype/cell stem origin 
There were 2 cases of M1 acute myeloid leukemia 
(AML-M1), 2 cases of AML-M4, 3 cases of AML not 
otherwise specified, 2 cases of chronic myelogenous 
leukemia (CML) aberrant translocation, and 1 case of 
refractory anemia (RA). 
Epidemiology 
The sex ratio is balanced (5M/5F).  
Median age, so far, is 62-65 years (range 36-83). 
Evolution 
Scarce data. One patient had a survival of 24 months 
(Lahortiga et al., 2004), a patient relapsed 6 months 
later and, eventually, died (survival: 9 months from 
diagnosis), and another one received standard induction 
chemotherapy without remission (survival: 4 months 
following diagnosis) (De Braekeleer et al., 2013). 
Prognosis 




Partial karyotype showing the double inv(3)(q21q26) and 
monosomy 7. 
Cytogenetics morphological 
Double inv(3)(q21q26); additional anomalies including 
-7. 
Cytogenetics molecular 
Splitting of the probe and rearrangement of the three 
fluorochromes. 
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FISH with EVI1 Breakapart Cytocell Aquarius probe showing a normal chromosome 3 and an inverted chromosome 3. 
 
Probes 
The EVI1 Breakapart Cytocell Aquarius probe contains 
three probes: a probe (encompassing 
D3S3364/D3S1614) labeled in Aqua of 562 kb in size 
centromeric to the EVI1 gene, a probe (encompassing 
D3S1282) labeled in Spectrum Green of 181 kb 
covering EVI1 and its flanking regions and a probe 
(encompassing D3S3523) labeled in Spectrum Orange 
of 124 kb telomeric to the EVI1 gene (telomeric of 
MYNN and covering LRRC34). 
Additional anomalies 
-7/del(7q) was seen in 4 cases. 
Genes involved and proteins 
Note 
The key event in the inv(3)(q21q26) is the 





EVI1 is a nuclear transcription factor that plays an 
essential role in the proliferation and maintenance of 
hematopoietic stem cells and can inhibit myeloid 
differentiation.  
Two alternative forms exists, one generated from EVI1, 
the other MECOM (MDS1 and EVI1 complex locus) 
through intergenic splicing with MDS1 
(myelodysplasia syndrome 1), a gene located 140 kb 
upstream of EVI1. 
DNA/RNA 
EVI1 has 16 exons, of whose 14 are coding. 
Transcription can initiate from different alternative 
exons. Several splice variants of the EVI1 mRNA have 
been described. 
Protein 
The protein encoded by this gene is a transcriptional 
regulator involved in cell differentiation and 
proliferation, and apoptosis. The encoded protein can 
interact with transcriptional coactivators (P/CAF, CBP) 
and corepressors (CTBP1, HDAC) as well as other 
transcription factors (GATA1, Smad3). 




RPN1 has 10 exons. Transcription leads to 8 alternative 
transcripts, of whose 2 are protein coding. 
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Protein 
This protein, which is a type I integral membrane 
protein found only in the rough endoplasmic reticulum, 
constitutes part of the regulatory subunit of the 26S 
proteasome. It may mediate binding of ubiquitin-like 
domains to this proteasome. 




RPN1 enhancer juxtaposed to EVI1. 
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